Pfizer continues its struggle regarding the agreement with Metsera.

Pfizer Inc. (NYSE: PFE) made a statement in response to the Delaware Chancery Court's rejection of a request for a temporary restraining order by Metsera, Inc. seeking to terminate the existing merger agreement. The company said, "We are confident in the merits of our claims and in our belief that Metsera has violated its contractual obligations. Today's decision does not address the substance of the legal issues at hand. Pfizer intends to vigorously pursue these claims through legal proceedings and in the ongoing antitrust case in Delaware federal court."

The company expressed its belief that Novo Nordisk's alleged unlawful plan to evade antitrust scrutiny would not succeed. Pfizer stated that Novo Nordisk's proposal is, in fact, misleading and cannot be deemed a superior offer under the terms of the existing merger agreement. Additionally, it emphasized that antitrust authorities worldwide, particularly in the United States, would not overlook Novo Nordisk's efforts to violate antitrust laws.

Yesterday, the Federal Trade Commission (FTC) sent a letter to Metsera and Novo Nordisk noting that no transaction can take place and that there could be reversals if such a transaction were to occur. Pfizer indicated that it would take steps to protect its rights under the previously signed agreement and believes this will benefit Metsera shareholders.